HA
PVLA

Herold Advisors’s Palvella Therapeutics PVLA Stock Holding History

Herold Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25
Closed -$6.06K – 698
2022
Q1 		$6.06K Buy
+25
New +$6.57K ﹤0.01% 658

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Herold Advisors's PVLA Position: Q4 2021 in Review

Herold Advisors sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 25 shares — an estimated $10K sold.

Herold Advisors first reported a position in PVLA in Q3 2021 and held it in 1 quarter. The position peaked at $10K in Q3 2021. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Herold Advisors reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Herold Advisors sold 25 Palvella Therapeutics shares in Q4 2021, an estimated $10K.
  • Herold Advisors first reported a position in Palvella Therapeutics in Q3 2021 and held it in 1 quarter.
  • Herold Advisors's Palvella Therapeutics position peaked at $10K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Herold Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.